EORTC Vestige Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled phase-2-study (VESTIGE) (Aktiv)
MK-7684A-005 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) (Aktiv)
RAMIRIS_AIO STO 0415 Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Gastric Cancer (Aktiv)